LAUSR

S ince the outbreak of the new coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) infection, lung ultrasound (US) has become a relevant tool in the point-of-care evaluation and monitoring of pulmonary alterations induced by SARS-CoV-2 infection at the bedside. We suggest in this commentary that US could also be effective to reduce lung inflammation and fibrosis in moderate-to-severe coronavirus disease 2019 (COVID-19)-related pneumonia. The new coronavirus infection, which started in December 2019 in Wuhan, China, is highly transmissible and primarily spreads through the respiratory tract by droplets, respiratory secretions, and direct contact. Coronavirus disease 2019 may cause constitutional symptoms, among which are respiratory and Manuscript accepted for publication September 7, 2020. All of the authors of this article have reported no disclosures. Address correspondence to Frederic Padilla, PhD, Focused Ultrasound Foundation, 1230 Cedars Ct, Charlottesville, VA 22903, USA. E-mail: [email protected]